Dr Reddy's enters into definitive agreement with BioDelivery Sciences International

05 Aug 2021 Evaluate

Dr Reddy's Laboratories has entered into a definitive agreement with BioDelivery Sciences International, Inc., to sell its US and Canada territory rights for Elyxyb 25 mg/mL to the US-based firm. Elyxyb is indicated for the acute treatment of migraine with or without aura in adults.

Under the terms of the pact, Dr Reddy's will receive $6 million upfront upon closing, followed by $ 9 million one year from closing. Further, it is eligible to receive event-based, sales-based milestones and quarterly earn-out payments.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1224.30 -15.70 (-1.27%)
28-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1328.25
Zydus Lifesciences 896.60
Lupin 2121.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×